Testosterone not associated with an increase in incident CV events: Study
Testosterone use was not associated with an increase in incident CV events in this patient population, suggests a study published in the Journal of the American Heart Association.
Testosterone treatment is common in men, although risks for major cardiovascular events are unclear.
A group of researchers from U.S.A conducted in US male veterans, aged ≥40 years, with low serum testosterone and multiple medical comorbidities and without a history of myocardial infarction, stroke, venous thromboembolism, prostate cancer, or testosterone treatment in the prior year.
For the primary outcome, we examined if testosterone treatment was associated with a composite cardiovascular outcome (incident myocardial infarction, ischemic stroke, or venous thromboembolism).
Testosterone use was modelled as intramuscular or transdermal and as current use, former use, and no use. Current testosterone users were compared with former users to reduce confounding by indication.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.